UK pharma major AstraZeneca (LSE: AZN) this morning released new Phase III data on two of its oncology drugs, showing positive results in lung cancer survival.
First up, high-level results from the ADAURA Phase III trial showed that Tagrisso (osimertinib) demonstrated a statistically-significant and clinically-meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
AstraZeneca has previously announced that Tagrisso demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in this setting. In September last year, updated results demonstrated a median DFS of nearly five and a half years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze